Extraordinary General Meeting results

RNS Number : 6747X

The MedicX Fund Limited

17 February 2012

 



Press Release

For immediate release                                                                                    

17 February 2012

MedicX Fund Limited

("MedicX Fund", the "Fund" or the "Company")

Extraordinary General Meeting results

The Board of MedicX Fund Limited is pleased to announce that at the Extraordinary General Meeting of its Shareholders held at 11:30 a.m. on 17 February 2012, the resolutions were duly passed as special resolutions without amendment by the required majority.  The details of each resolution are as follows: 

1. SPECIAL RESOLUTION	IT WAS RESOLVED that the directors of the Company from time to time (the "Board") be and are generally authorised to allot up to 70,000,000 Ordinary Shares (within the meaning given in the Company's Articles of Incorporation (the "Articles")) for cash, and in accordance with Article 13.5, the provisions contained in Article 13.3 of the Articles (rights of pre-emption) shall not apply to any such allotment, provided that: (a)     this authorisation shall (unless previously revoked, varied or renewed by the Company) expire on the conclusion of the Company's next annual general meeting, to be held in 2013, save that the Company may make prior to such expiry an offer or agreement which would or might require shares to be allotted after expiry of such period and the Board may allot shares pursuant to such an offer or agreement notwithstanding the expiry of the authority given by this resolution; and (b)     this power shall be limited to the allotment of ordinary shares in the Company's capital in connection with the Placing, Open Offer and Offer for Subscription (as such terms are defined in the prospectus issued by the Company dated 30 January 2012, a copy of which is produced to the meeting and initialled by the Chairman for the purposes of identification).
	In Favour - 84,784,197 (99.5%) Against - 459,195 (0.5%) Withheld - 56,867
2. SPECIAL RESOLUTION	THAT the issue by the Company of between 5,000,000 and up to 20,000,000 New Ordinary Shares (as defined in the prospectus issued by the Company dated 30 January 2012, a copy of which is produced to the meeting and initialled by the Chairman for the purposes of identification) to Collins Stewart at the Issue Price on terms that they will be purchased back by the Company at the Issue Price and held in treasury be and is hereby approved PROVIDED THAT this authority shall expire on 30 April 2012 (save that the Company may prior to such expiry make an offer to purchase shares for delivery to the Company after 30 April 2012).
	In Favour - 84,784,197 (99.5%) Against - 459,195 (0.5%) Withheld - 56,867

Notes:

·          The votes "for" the resolution are calculated as the aggregate of proxy instructions voting "for" the resolution and the votes at the Chairman's discretion.

·          A vote "withheld" is not a vote in law and is not calculated in the proportion of the votes "for" and "against" the resolution.

·          The total number of voting rights at the proxy deadline was 193,645,780.

For further information please contact:

MedicX Fund                                                                              [phone]

David Staples, Chairman                                                            

MedicX Group                                                                            [phone]

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Collins Stewart Europe Limited                                                    [phone]

Andrew Zychowski / Helen Goldsmith

Buchanan Communications                                                          [phone]

Charles Ryland / Suzanne Brocks

Information on MedicX Fund Limited

MedicX Fund Limited is a specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 65 properties.

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Services Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 26 people operating across the UK. 

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

END

 

 

REGBLGDDGSBBGDR